Last reviewed · How we verify
Influenza (Influenza and COVID-19 Combination B)
Influenza (generic name: Influenza and COVID-19 Combination B) is a Non-Standardized Plant Allergenic Extract [EPC] Biologic drug developed by BioNTech. It is currently FDA-approved for aches, cold symptoms, cramping.
Influenza and COVID-19 Combination B is a marketed drug by BioNTech SE. It targets aches, cold symptoms, cramping, discomfort, and fatigue. The mechanism of action is not specified. This drug is commercially significant with $21.2B in revenue. There are 9 clinical trials. However, there are no publications available. The pipeline developments are not specified.
At a glance
| Generic name | Influenza and COVID-19 Combination B |
|---|---|
| Sponsor | BioNTech |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Target | Not specified |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- aches
- cold symptoms
- cramping
- discomfort
- fatigue
- labored breathing
- flu symptoms
- vomiting
Common side effects
- Runny nose or nasal congestion
- Fever over 100°F
- Sore throat
- Wheezing (6-23 months)
- Hospitalization (6-23 months)
- Wheezing (24-59 months)
- Hospitalization (24-59 months)
Serious adverse events
- Asthma events (children younger than 5 years)
- Wheezing requiring bronchodilator therapy or accompanied by respiratory distress or hypoxia (6-23 months)
- Hospitalization due to any cause (6-23 months)
Drug interactions
- Amiodarone
- Azithromycin
- Cobicistat
- Dofetilide
- Erythromycin
- Flecainide
- Itraconazole
- Ketoconazole
- Lopinavir/Ritonavir
- Methadone
- Pimozide
- Quinidine
Key clinical trials
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)
- A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (PHASE2)
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old (PHASE1, PHASE2)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza CI brief — competitive landscape report
- Influenza updates RSS · CI watch RSS
- BioNTech portfolio CI
Frequently asked questions about Influenza
What is Influenza?
Influenza (Influenza and COVID-19 Combination B) is a Non-Standardized Plant Allergenic Extract [EPC] drug developed by BioNTech, indicated for aches, cold symptoms, cramping.
What is Influenza used for?
Influenza is indicated for aches, cold symptoms, cramping, discomfort, fatigue.
Who makes Influenza?
Influenza is developed and marketed by BioNTech (see full BioNTech pipeline at /company/biontech).
What is the generic name of Influenza?
Influenza and COVID-19 Combination B is the generic (nonproprietary) name of Influenza.
What drug class is Influenza in?
Influenza belongs to the Non-Standardized Plant Allergenic Extract [EPC] class. See all Non-Standardized Plant Allergenic Extract [EPC] drugs at /class/non-standardized-plant-allergenic-extract-epc.
What development phase is Influenza in?
Influenza is FDA-approved (marketed).
What are the side effects of Influenza?
Common side effects of Influenza include Runny nose or nasal congestion, Fever over 100°F, Sore throat, Wheezing (6-23 months), Hospitalization (6-23 months), Wheezing (24-59 months). Serious adverse events: Asthma events (children younger than 5 years), Wheezing requiring bronchodilator therapy or accompanied by respiratory distress or hypoxia (6-23 months), Hospitalization due to any cause (6-23 months).
What does Influenza target?
Influenza targets Not specified and is a Non-Standardized Plant Allergenic Extract [EPC].
Related
- Drug class: All Non-Standardized Plant Allergenic Extract [EPC] drugs
- Target: All drugs targeting Not specified
- Manufacturer: BioNTech — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for aches
- Indication: Drugs for cold symptoms
- Indication: Drugs for cramping
- Compare: Influenza vs similar drugs
- Pricing: Influenza cost, discount & access